Company: CMND
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001213900-25-109567
Chunk: 22

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 22
---
 factors they believe to be appropriate.

Important factors that could
cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors
could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements,
including, but not limited to, the factors summarized below:

| ● | the ability of our pre-clinical and any future clinical trials to demonstrate safety and efficacy of our future product candidates, and other positive results; |

| ● | the timing and focus of our future preclinical studies and clinical trials, and the reporting of data from those studies and trials; |

| ● | the size of the market opportunity for our future product candidates, including our estimates of the number of patients who suffer from the diseases we are targeting; |

| ● | the success of competing therapies that are or may become available; |

| ● | the beneficial characteristics, safety, efficacy and therapeutic effects of our future product candidates, as well as the potential healthcare costs saved through utilizing our future product candidates; |

| ● | the ability of our future product candidates to address needs not currently addressed by the psychedelic industry; |

| ● | the ability of our future product candidates to address needs not currently addressed by the psychedelic industry; |

| ● | our ability to obtain and maintain regulatory approval of our future product candidates; |

| ● | our plans relating to the further development of our future product candidates, including additional disease states or indications we may pursue; |

| ● | existing regulations and regulatory developments in the United States and other jurisdictions; |

| ● | our plans and ability to obtain or protect intellectual property rights, including extensions of patent terms where available and our ability to avoid infringing the intellectual property rights of others; |

| ● | the ability of our management team to oversee our drug research programs; |

<div align='center'>S-10</div>

| ● | the need to hire additional personnel and our ability to attract and retain such personnel; |

| ● | our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; |

| ● | our dependence on third parties; |

| ● | our ability to compete with other companies who offer products that address similar issues that our future product candidates will address; |

| ● | our financial performance; |

| ● | the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements; |

| ● | our ability to generate revenue and profit margin under our